Literature DB >> 17306604

Association between the TP53 codon72 polymorphism and oral cancer risk and prognosis.

Yoshiki Kuroda1, Hiroyuki Nakao, Kunio Ikemura, Takahiko Katoh.   

Abstract

The TP53 codon72 polymorphism has recently been extensively studied to determine the risk factor for carcinogenesis. However, there are few reports about the relationship between the TP53 codon72 polymorphism and oral cancer risk or post treatment prognosis. We evaluated the genotypic distribution of the TP53 codon72 polymorphism in 100 oral cancer cases and 271 non-cancer controls. There were no significant differences in the frequencies of the three genotypes (Arg/Arg, Arg/Pro, Pro/Pro) of the TP53 codon72 polymorphism between oral cancer cases and controls. However, stratifying by smoking status, we found that the adjusted odds ratio for non-smokers with the Pro/Pro genotype was significantly increased (adjusted OR=2.70, 95% confidence interval=1.07-6.82). We also found that the cases with the Pro/Pro genotype tended to have a shorter post-treatment survival compared with those with the Arg/Pro genotype (p=0.06). Our results suggest the Pro/Pro genotype of the TP53 codon72 polymorphism increases oral cancer risk in non-smokers and worsens their prognosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17306604     DOI: 10.1016/j.oraloncology.2006.12.001

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  9 in total

1.  No significant association between p53 codon 72 Arg/Pro polymorphism and risk of oral cancer.

Authors:  Ning Jiang; Jie Pan; Lei Wang; Yin-Zhong Duan
Journal:  Tumour Biol       Date:  2012-11-29

Review 2.  Molecular techniques and genetic alterations in head and neck cancer.

Authors:  Patrick K Ha; Steven S Chang; Chad A Glazer; Joseph A Califano; David Sidransky
Journal:  Oral Oncol       Date:  2008-07-31       Impact factor: 5.337

3.  p53 codon 72 polymorphism as a progression index for bladder cancer.

Authors:  Hung-Yu Lin; Chun-Hsiung Huang; Tsan-Jung Yu; Wen-Jen Wu; Ming-Chang Yang; For-Wey Lung
Journal:  Oncol Rep       Date:  2011-12-22       Impact factor: 3.906

4.  Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma.

Authors:  Yasuki Hori; Katsuyuki Miyabe; Michihiro Yoshida; Takahiro Nakazawa; Kazuki Hayashi; Itaru Naitoh; Shuya Shimizu; Hiromu Kondo; Yuji Nishi; Shuichiro Umemura; Akihisa Kato; Hirotaka Ohara; Hiroshi Inagaki; Takashi Joh
Journal:  PLoS One       Date:  2015-03-03       Impact factor: 3.240

5.  P53 codon 72 polymorphism, human papillomavirus infection, and their interaction to oral carcinoma susceptibility.

Authors:  Jun Hou; Ying Gu; Wei Hou; Song Wu; Yin Lou; Wenyu Yang; Ling Zhu; Yukun Hu; Ming Sun; Haowei Xue
Journal:  BMC Genet       Date:  2015-06-30       Impact factor: 2.797

6.  Effect of TP53 rs1042522 on the susceptibility of patients to oral squamous cell carcinoma and oral leukoplakia: a meta-analysis.

Authors:  Zhen Sun; Wei Gao; Jiang-Tao Cui
Journal:  BMC Oral Health       Date:  2018-08-20       Impact factor: 2.757

7.  Meta-Analysis Results on the Association Between TP53 Codon 72 Polymorphism With the Susceptibility to Oral Cancer.

Authors:  Ying-Mei Lin; Jun Shao; Xiao-Hong Yin; CaiCai Huang; Xiao-Wei Jia; Ya-Di Yuan; Chang-Jing Wu; En-Ming Zhen; Zhong-Xiong Yao; Xian-Tao Zeng; Rui-Hua Liu
Journal:  Front Physiol       Date:  2018-08-02       Impact factor: 4.566

8.  A compensatory role of NF-κB to p53 in response to 5-FU-based chemotherapy for gastric cancer cell lines.

Authors:  Fumitaka Endo; Satoshi S Nishizuka; Kohei Kume; Kazushige Ishida; Hirokatsu Katagiri; Kaoru Ishida; Kei Sato; Takeshi Iwaya; Keisuke Koeda; Go Wakabayashi
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

9.  Association between the TP53 codon 72 polymorphism and risk of oral squamous cell carcinoma in Asians: a meta-analysis.

Authors:  Xian-Tao Zeng; Wei Luo; Pei-Liang Geng; Yi Guo; Yu-Ming Niu; Wei-Dong Leng
Journal:  BMC Cancer       Date:  2014-06-26       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.